ABSTRACT
The timing of sodium bicarbonate (NaHCO3) supplementation has been suggested to be most optimal when coincided with a personal time that bicarbonate (HCO3-) or pH peaks in the blood following ingestion. However, the ergogenic mechanisms supporting this ingestion strategy are strongly contested. It is therefore plausible that NaHCO3 may be ergogenic by causing beneficial shifts in the strong ion difference (SID), though the time course of this blood acid base balance variable is yet to be investigated. Twelve highly trained, adolescent swimmers (age: 15.9 ± 1.0 years, body mass: 65.3 ± 9.6 kg) consumed their typical pre-competition nutrition 1-3 hours before ingesting 0.3 gâkg BM-1 NaHCO3 in gelatine capsules. Capillary blood samples were then taken during seated rest on nine occasions (0, 60, 75, 90, 105, 120, 135, 150, 165 min post-ingestion) to identify the time course changes in HCO3-, pH, and the SID. No significant differences were found in the time to peak of each blood measure (HCO3-: 130 ± 35 min, pH: 120 ± 38 min, SID: 98 ± 37 min; p = 0.08); however, a large effect size was calculated between time to peak HCO3- and the SID (g = 0.88). Considering that a difference between time to peak blood HCO3- and the SID was identified in adolescents, future research should compare the ergogenic effects of these two individualized NaHCO3 ingestion strategies compared to a traditional, standardized approach.
Subject(s)
Acid-Base Equilibrium/physiology , Athletes , Bicarbonates/blood , Sodium Bicarbonate/administration & dosage , Adolescent , Eructation/etiology , Female , Humans , Hydrogen-Ion Concentration , Male , Nausea/etiology , Performance-Enhancing Substances/administration & dosage , Performance-Enhancing Substances/adverse effects , Performance-Enhancing Substances/chemistry , Sodium Bicarbonate/adverse effects , Sodium Bicarbonate/chemistry , SwimmingABSTRACT
RATIONALE: The metabolism of arimistane (Arim) was first described in 2015, and androst-3,5-diene-7ß-ol-17-one was proposed as the main metabolite excreted in urine. Recently, a more detailed study describing the findings in urine after the administration of Arim has been published. This study corroborated the previously described metabolite but also described several phase I and II metabolites, analyzing trimethylsilylated urinary extracts using accurate mass spectrometry coupled to gas chromatography (GC/qTOF). The present communication is an extension of this late investigation aiming to implement the results of Arim metabolism using either accurate mass spectrometry and/or triple quadrupole tandem mass spectrometry, both coupled to liquid chromatography (LC/qTOF and LC/QqQ). METHODS: The samples used in this study were the same as previously studied using GC/qTOF. One single oral dose of Arim was administered to three volunteers, and samples collected before and up to 10 h after the Arim administration were analyzed. The unconjugated fraction of urine was removed, and the hydrolysis was performed with ß-glucuronidase from Escherichia coli. The extracts were reconstituted in water:acetonitrile before the LC/qTOF and LC/QqQ analysis. RESULTS: The presence of the proposed metabolites studied using GC was verified by accurate mass measurements. Twelve metabolites not found in the blank urine samples were identified by the accurate mass spectra with acceptable errors between -7.5 and 8.1 ppm: 4 reduced metabolites, 4 monohydroxylated metabolites, and 4 with an additional hydroxylation (bis-hydroxylated metabolites). Unlike in the study carried out using GC/qTOF, Arim itself was found in the samples of the three volunteers. CONCLUSIONS: Twelve metabolites were identified, and specific transitions were proposed. Despite the good results, some limitations remain. As for GC/qTOF, the α- or ß configuration of hydroxy groups, as well as the exact position for some unsaturation, cannot be assigned with certainty. Because certified reference materials of these metabolites are not yet available, the molecular structures were hypothesized considering the previous study using GC.
Subject(s)
Performance-Enhancing Substances/urine , Pharmaceutical Preparations/urine , Chromatography, High Pressure Liquid/methods , Doping in Sports/methods , Gas Chromatography-Mass Spectrometry/methods , Humans , Molecular Structure , Performance-Enhancing Substances/chemistry , Urine/chemistryABSTRACT
Higenamine was included in the World Anti-Doping Agency (WADA) Prohibited Substances and Methods List as a ß2 -adrenoceptor agonist in 2017, thereby resulting in its prohibition both in and out of competition. The present mini review describes the physiology and pharmacology of adrenoceptors, summarizes the literature addressing the mechanism of action of higenamine and extends these findings with previously unpublished in silico and in vitro work. Studies conducted in isolated in vitro systems, whole-animal preparations and a small number of clinical studies suggest that higenamine acts in part as a ß2 -adrenoceptor agonist. In silico predictive tools indicated that higenamine and possibly a metabolite have a high probability of interacting with the ß2 -receptor as an agonist. Stable expression of human ß2 -receptors in Chinese hamster ovary (CHO) cells to measure agonist activity not only confirmed the activity of higenamine at ß2 but also closely agreed with the in silico prediction of potency for this compound. These data confirm and extend literature findings supporting the inclusion of higenamine in the Prohibited List.
Subject(s)
Adrenergic beta-Agonists/pharmacology , Alkaloids/pharmacology , Performance-Enhancing Substances/pharmacology , Receptors, Adrenergic, beta-2/metabolism , Tetrahydroisoquinolines/pharmacology , Adrenergic beta-Agonists/chemistry , Alkaloids/chemistry , Animals , Athletic Performance , Doping in Sports , Humans , Performance-Enhancing Substances/chemistry , Tetrahydroisoquinolines/chemistrySubject(s)
Cannabis/chemistry , Cannabis/metabolism , Exercise/physiology , Exercise/psychology , Marijuana Use/metabolism , Performance-Enhancing Substances/chemistry , Performance-Enhancing Substances/metabolism , Adult , Arachidonic Acids/metabolism , Athletic Performance/physiology , Cannabidiol/metabolism , Cannabis/adverse effects , Doping in Sports/legislation & jurisprudence , Doping in Sports/prevention & control , Dronabinol/metabolism , Endocannabinoids/metabolism , Female , Humans , Inflammation/metabolism , Inflammation/prevention & control , Male , Marijuana Use/adverse effects , Motivation , Performance-Enhancing Substances/adverse effects , Polyunsaturated Alkamides/metabolism , Reproducibility of Results , Young AdultABSTRACT
Caffeine is a well-established ergogenic aid, with its performance-enhancing effects replicated across a variety of exercise types. Caffeine exerts its performance-benefits through many mechanisms, including acting as an adenosine receptor antagonist, and serving to reduce sensations of fatigue and pain. One potential mechanism that is currently underexplored is whether caffeine's bitter taste mediates some of its ergogenic effects, which is discussed in this article. Previous research has demonstrated that bitter tastants have the ability to enhance performance, and this effect is mediated by bitter taste receptors in the mouth and gastrointestinal tract. Additionally, the ability to detect bitter tastes is subject to individual variation, raising the potential that the demonstrated inter-individual response to a standardised caffeine dose is potentially driven by differences in taste response. Finally, it appears that some of caffeine's performance-enhancing effects are driven by expectancy. As bitter taste may serve as a signal that caffeine has been ingested, it is possible that some of the expectancy effects of caffeine ingestion are driven by its bitter taste. These aspects all have potentially important implications for future research, as well as for how athletes and coaches utilise caffeine around competition, both of which are explored in depth here.
Subject(s)
Caffeine/pharmacology , Models, Biological , Performance-Enhancing Substances/pharmacology , Receptors, G-Protein-Coupled/drug effects , Taste , Anticipation, Psychological , Athletic Performance , Biological Variation, Individual , Caffeine/administration & dosage , Caffeine/chemistry , Carbohydrates/administration & dosage , Carbohydrates/pharmacology , Conditioning, Psychological , Cues , Gastrointestinal Tract/drug effects , Gastrointestinal Tract/physiology , Humans , Models, Psychological , Mouthwashes , Performance-Enhancing Substances/chemistry , Receptors, G-Protein-Coupled/physiology , Taste Perception/geneticsABSTRACT
BACKGROUND: Bodybuilding supplements can cause a profound cholestatic syndrome. AIM: To describe the drug-Induced liver injury network's experience with liver injury due to bodybuilding supplements. METHODS: Liver injury pattern, severity and outcomes, potential genetic associations, and exposure to anabolic steroids by product analysis were analysed in prospectively enrolled subjects with bodybuilding supplement-induced liver injury with causality scores of probable or higher. RESULTS: Forty-four males (mean age 33 years) developed liver injury with a median latency of 73 days. Forty-one per cent presented with hepatocellular pattern of liver injury as defined by the R > 5 ([Fold elevation of ALT] ÷ [Fold elevation of Alk Phos] (mean, range = 6.4, 0.5-31.4, n = 42) despite all presenting with clinical features of cholestatic liver injury (100% with jaundice and 84% with pruritus). Liver biopsy (59% of subjects) demonstrated a mild hepatitis and profound cholestasis in most without bile duct injury, loss or fibrosis. Seventy-one per cent were hospitalised, and none died or required liver transplantation. In some, chemical analysis revealed anabolic steroid controlled substances not listed on the label. No enrichment of genetic variants associated with cholestatic syndromes was found, although mutations in ABCB11 (present in up to 20%) were significantly different than in ethnically matched controls. CONCLUSIONS: Patients with bodybuilding supplements liver injury uniformly presented with cholestatic injury, which slowly resolved. The ingested products often contained anabolic steroids not identified on the label, and no enrichment in genetic variants was found, indicating a need for additional studies.
Subject(s)
Chemical and Drug Induced Liver Injury/epidemiology , Cholestasis/chemically induced , Dietary Supplements/adverse effects , Muscles , Performance-Enhancing Substances/adverse effects , ATP Binding Cassette Transporter, Subfamily B, Member 11/genetics , Adult , Biopsy , Chemical and Drug Induced Liver Injury/genetics , Chemical and Drug Induced Liver Injury/pathology , Cholestasis/epidemiology , Cholestasis/genetics , Cholestasis/therapy , Dietary Supplements/analysis , Genetic Predisposition to Disease/epidemiology , Humans , Liver Transplantation/statistics & numerical data , Male , Middle Aged , Muscles/drug effects , Muscles/pathology , Performance-Enhancing Substances/analysis , Performance-Enhancing Substances/chemistry , Risk Factors , Severity of Illness Index , Somatotypes/physiology , Young AdultABSTRACT
BACKGROUND: International studies have shown that 12-58 % of all dietary supplements intended for people who exercise and engage in sports contain substances prohibited by the World Anti-Doping Code (WADC). In some cases, the doping substances are not declared on the product label, and the consumer may therefore be unaware of what he/she ingests. Many of the substances may cause adverse health effects, and sale of such products is illegal in Norway. MATERIAL AND METHOD: To investigate the prevalence of doping substances in dietary supplements sold on the Norwegian market, a total of 93 high-risk products from online shops targeting Norwegian consumers were analysed for substances on the WADC Prohibited List and pharmaceutical drugs. All supplements were marketed as able to boost energy levels and/or having a muscle-building or fat-burning effect. The products were selected on the basis of tips received, online forums and/or international lists. RESULTS: Altogether 21 of 93 (23 %) products analysed contained prohibited substances, pharmaceutical drugs and/or illegal amounts of caffeine. Substances on the WADC Prohibited List were detected in 8 of the 93 (9 %) dietary supplements. All products containing doping substances were declared as containing one or more banned substances. INTERPRETATION: The results show that using apparently legal dietary supplements purchased in online shops targeting Norwegian consumers involves a risk of inadvertent doping and adverse health effects.
Subject(s)
Dietary Supplements/analysis , Performance-Enhancing Substances/chemistry , Anabolic Agents/chemistry , Anti-Obesity Agents/chemistry , Caffeine/chemistry , Doping in Sports , Humans , Internet , Norway , Pharmaceutical Preparations/chemistryABSTRACT
Essence of chicken is a popular Asian nutritional supplement that is often taken to improve metabolism and general health. Although used as a traditional remedy for combating fatigue and general health, there has been few studies investigating the ergogenic properties of chicken essence and its associated mechanism. We conducted a study to investigate the anti-fatigue and anti-oxidant properties of essence of chicken (EC) after exercise. Six weeks old male Institute of Cancer Research (ICR) mice were divided to four groups (10 mice/group) and were provided different doses of Essence of Chicken (EC): (1) Vehicle (water), (2) EC-0.5X (558 mg/kg), (3) EC-1X (1117 mg/kg), and (4) EC-2X (2234 mg/kg). EC supplementation could improve endurance and grip strength (p < 0.0001) and it had significant effects on the fatigue-related biochemical markers: ammonia, blood urea nitrogen (BUN), and creatine kinase (CK) levels were significantly lowered, while glucose blood levels and lactate clearance were improved after exercise challenge. Muscle and liver glycogen levels, muscle and liver superoxide dismutase (SOD), hepatic catalase (CAT), and glutathione (GSH) levels were observed to increase with EC supplementation. Preliminary in vitro data suggests that EC may have a beneficial effect in muscle mass and strength. No abnormalities were observed from pathohistological examination. Our study suggests that the EC could significantly improve exercise performance and endurance capacity and that the anti-oxidant properties of EC may be an important contributing factor to its anti-fatigue effects.
Subject(s)
Chickens , Muscle Strength/drug effects , Performance-Enhancing Substances/pharmacology , Physical Endurance/drug effects , Poultry Products , Animals , Antioxidants/chemistry , Antioxidants/pharmacology , Body Weight/drug effects , Cell Line , Eating/drug effects , Male , Medicine, Chinese Traditional , Mice , Mice, Inbred ICR , Oxidative Stress/drug effects , Performance-Enhancing Substances/chemistry , SwimmingABSTRACT
4-Hydroxyandrost-4-ene-3,17-dione, also named formestane, is an irreversible aromatase inhibitor and therapeutically used as anti-breast cancer medication in post-menopausal women. Currently, no therapeutical indication led to approval of its 17-hydroxylated analog 4-hydroxytestosterone, an anabolic steroid. However, it is currently investigated in a clinical trial for breast cancer. In context with sports doping, aromatase inhibitors are administered to reduce estrogenic side effects of misused anabolic substances or their metabolites. Therefore, both substances are prohibited in sports by the World Anti-Doping Agency (WADA). Analysis of urinary phase I and phase II metabolites showed similar results for both compounds. In the current investigation, 4-hydroxyandrost-4-ene-3,17-dione, 4-hydroxytestosterone and seven of their described urinary metabolites as well as 2α-hydroxyandrostenedione were tested in the yeast androgen screen and the yeast estrogen screen. Androgenic effects were observed for all tested substances, except for one, which showed anti-androgenic properties. With regard to the yeast estrogen screen, estrogenic effects were observed for only two metabolites at rather high concentrations, while six out of the ten substances tested showed anti-estrogenic properties. In terms of the strong androgenic effect observed for 4-hydroxytestosterone (10-8â¯M), 4-hydroxyandrost-4-ene-3,17-dione (10-8â¯M) and two more urinary metabolites, the yeast androgen assay may also be used to trace abuse in urine samples.
Subject(s)
Androgens/pharmacology , Androstenedione/analogs & derivatives , Doping in Sports , Estrogen Receptor alpha/agonists , Estrogens/pharmacology , Hydroxytestosterones/pharmacology , Performance-Enhancing Substances/pharmacology , Receptors, Androgen/drug effects , Substance Abuse Detection/methods , Testosterone Congeners/pharmacology , Yeasts/drug effects , Androgens/chemistry , Androstenedione/chemistry , Androstenedione/metabolism , Androstenedione/pharmacology , Biotransformation , Dose-Response Relationship, Drug , Estrogen Receptor alpha/chemistry , Estrogen Receptor alpha/genetics , Estrogen Receptor alpha/metabolism , Estrogens/chemistry , Estrogens/metabolism , Humans , Hydroxytestosterones/chemistry , Hydroxytestosterones/metabolism , Molecular Docking Simulation , Performance-Enhancing Substances/chemistry , Performance-Enhancing Substances/metabolism , Protein Conformation , Receptors, Androgen/chemistry , Receptors, Androgen/genetics , Receptors, Androgen/metabolism , Testosterone Congeners/chemistry , Testosterone Congeners/metabolism , Yeasts/genetics , Yeasts/metabolismABSTRACT
PURPOSE: The aim of this study is to use computational approaches to predict the ADME-Tox profiles, pharmacokinetics, molecular targets, biological activity spectra and side/toxic effects of 31 anabolic and androgen steroids in humans. METHODS: The following computational tools are used: (i) FAFDrugs4, SwissADME and admetSARfor obtaining the ADME-Tox profiles and for predicting pharmacokinetics;(ii) SwissTargetPrediction and PASS online for predicting the molecular targets and biological activities; (iii) PASS online, Toxtree, admetSAR and Endocrine Disruptomefor envisaging the specific toxicities; (iv) SwissDock to assess the interactions of investigated steroids with cytochromes involved in drugs metabolism. RESULTS: Investigated steroids usually reveal a high gastrointestinal absorption and a good oral bioavailability, may inhibit someof the human cytochromes involved in the metabolism of xenobiotics (CYP2C9 being the most affected) and reflect a good capacity for skin penetration. There are predicted numerous side effects of investigated steroids in humans: genotoxic carcinogenicity, hepatotoxicity, cardiovascular, hematotoxic and genitourinary effects, dermal irritations, endocrine disruption and reproductive dysfunction. CONCLUSIONS: These results are important to be known as an occupational exposure to anabolic and androgenic steroids at workplaces may occur and because there also is a deliberate human exposure to steroids for their performance enhancement and anti-aging properties.
Subject(s)
Anabolic Agents/pharmacology , Androgens/pharmacology , Models, Biological , Performance-Enhancing Substances/pharmacology , Anabolic Agents/chemistry , Androgens/chemistry , Athletes , Computer Simulation , Designer Drugs/chemistry , Designer Drugs/pharmacology , Drug Interactions , Drug Misuse/adverse effects , Humans , Molecular Docking Simulation , Occupational Exposure/adverse effects , Performance-Enhancing Substances/chemistry , Skin Absorption , Veterinary Drugs/chemistry , Veterinary Drugs/pharmacology , WorkplaceABSTRACT
Phenethylamines (PEAs) are popular substances found in weight-loss and sports nutrition supplements. They are generally pharmacologically active and primarily affect the sympathetic nervous system. Many PEAs are synthetic chemicals and are on the prohibited list of the World Anti-Doping Agency. In this study, nuclear magnetic resonance (NMR) spectroscopy was applied to detect and identify the presence of PEAs in sports dietary supplements without the need for chromatographic separation or pre-knowledge on formulation. Eight PEAs, viz. phenethylamine, synephrine, oxilofrine, hordenine, ß-methylphenethylamine, N-methyltyramine, octopamine and deterenol, were identified from 32 dietary supplements sold in the US market. Furthermore, a quantitative NMR method was developed and validated for simultaneous determination of the concentrations of the PEAs. The study demonstrated that NMR could be a potential tool to monitor and detect PEAs or other ingredients in dietary supplements.
Subject(s)
Diosgenin/analysis , Doping in Sports/prevention & control , Performance-Enhancing Substances/analysis , Phenethylamines/analysis , Phytosterols/analysis , Proton Magnetic Resonance Spectroscopy/methods , Deuterium/chemistry , Diosgenin/chemistry , Humans , Performance-Enhancing Substances/chemistry , Phenethylamines/chemistry , Phytosterols/chemistry , Proton Magnetic Resonance Spectroscopy/instrumentation , Staining and Labeling/methodsABSTRACT
Several high-profile revelations concerning anti-doping rule violations over the past 12 months have outlined the importance of tackling prevailing challenges and reducing the limitations of the current anti-doping system. At this time, the necessity to enhance, expand, and improve analytical test methods in response to the substances outlined in the World Anti-Doping Agency's (WADA) Prohibited List represents an increasingly crucial task for modern sports drug-testing programs. The ability to improve analytical testing methods often relies on the expedient application of novel information regarding superior target analytes for sports drug-testing assays, drug elimination profiles, alternative test matrices, together with recent advances in instrumental developments. This annual banned-substance review evaluates literature published between October 2016 and September 2017 offering an in-depth evaluation of developments in these arenas and their potential application to substances reported in WADA's 2017 Prohibited List.
Subject(s)
Doping in Sports/prevention & control , Performance-Enhancing Substances/analysis , Performance-Enhancing Substances/chemistry , Substance Abuse Detection/methods , Doping in Sports/legislation & jurisprudence , Humans , Performance-Enhancing Substances/blood , Substance Abuse Detection/legislation & jurisprudenceABSTRACT
Importance: Recent reports have described the increasing use of nonsteroidal selective androgen receptor modulators, which have not been approved by the US Food and Drug Administration (FDA), to enhance appearance and performance. The composition and purity of such products is not known. Objective: To determine the chemical identity and the amounts of ingredients in dietary supplements and products marketed and sold through the internet as selective androgen receptor modulators and compare the analyzed contents with product labels. Design and Setting: Web-based searches were performed from February 18, 2016, to March 25, 2016, using the Google search engine on the Chrome and Internet Explorer web browsers to identify suppliers selling selective androgen receptor modulators. The products were purchased and the identities of the compounds and their amounts were determined from April to August 2016 using chain-of-custody and World Anti-Doping Association-approved analytical procedures. Analytical findings were compared against the label information. Exposures: Products marketed and sold as selective androgen receptor modulators. Main Outcomes and Measures: Chemical identities and the amount of ingredients in each product marketed and sold as selective androgen receptor modulators. Results: Among 44 products marketed and sold as selective androgen receptor modulators, only 23 (52%) contained 1 or more selective androgen receptor modulators (Ostarine, LGD-4033, or Andarine). An additional 17 products (39%) contained another unapproved drug, including the growth hormone secretagogue ibutamoren, the peroxisome proliferator-activated receptor-δ agonist GW501516, and the Rev-ErbA agonist SR9009. Of the 44 tested products, no active compound was detected in 4 (9%) and substances not listed on the label were contained in 11 (25%). In only 18 of the 44 products (41%), the amount of active compound in the product matched that listed on the label. The amount of the compounds listed on the label differed substantially from that found by analysis in 26 of 44 products (59%). Conclusions and Relevance: In this limited investigation involving chemical analyses of 44 products marketed as selective androgen receptor modulators and sold via the internet, most products contained unapproved drugs and substances. Only 52% contained selective androgen receptor modulators and many were inaccurately labeled.
Subject(s)
Anabolic Agents/chemistry , Commerce , Drug Labeling , Internet , Performance-Enhancing Substances/chemistry , Receptors, Androgen , Acetamides/analysis , Aminophenols/analysis , Anilides/analysis , Drug Approval , Drug Trafficking , Nitriles/analysis , Pyrrolidines/analysis , United States , United States Food and Drug AdministrationABSTRACT
INTRODUCTION: People injecting image and performance enhancing drugs (IPEDs) have traditionally not been perceived as being at high risk of hepatitis C virus (HCV) infection. However, recent studies indicate the HCV antibody (anti-HCV) prevalence in this group is 10-times that in the general population. HCV testing uptake and undiagnosed infections are examined using data from a voluntary unlinked-anonymous survey. METHOD: People injecting IPEDs across England and Wales completed a short bio-behavioural survey (2012-15). Anti-HCV status and self-reports of HCV testing were used in the analysis. RESULTS: The participants median age was 31 years, 98% were men, 14% had also injected psychoactive drugs and the anti-HCV prevalence was 4.8% (N=564). Among those who had never injected psychoactive drugs the anti-HCV prevalence was 1.4%; among those who had recently injected psychoactive drugs (preceding 12 months) prevalence was 39% and among those who had done this previously 14% (p<0.001). Overall, 37% had been tested for HCV: among those who had recently injected psychoactive drugs 78% had been tested, as had 56% of those who had injected psychoactive drugs previously; 33% of those never injecting psychoactive drugs were tested (p<0.001). Overall, 44% of those with anti-HCV were aware of this; however, only 14% of those who had never injected psychoactive drugs were aware. CONCLUSIONS: One-in-twenty people who inject IPEDs have anti-HCV. HCV infections among those who had never injected psychoactive drugs were mostly undiagnosed, though this group had a lower prevalence. Targeted HCV testing interventions are also needed for those injecting IPEDs.
Subject(s)
Hepacivirus , Hepatitis C Antibodies/blood , Performance-Enhancing Substances/pharmacology , Substance Abuse, Intravenous/epidemiology , England/epidemiology , Hepatitis C Antibodies/immunology , Humans , Performance-Enhancing Substances/chemistry , Prevalence , Surveys and Questionnaires , Wales/epidemiologyABSTRACT
The differentiation of clenbuterol abuse and unintentional ingestion from contaminated meat is crucial with respect to the valuation of an adverse analytical finding in human sports doping control. The proportion of the two enantiomers of clenbuterol may serve as potential discriminating parameter. For the determination of the individual enantiomers, specific methods were developed and validated for the different matrices under investigation based on chiral chromatography coupled to tandem mass spectrometry. Data are presented from the administration to humans of clenbuterol from a pharmaceutical preparation, and from cattle meat and liver containing residues. A shift in the proportion of the enantiomers in cattle meat is detected and this signature is also found in human urine after ingestion. Thus, an altered enantiomeric composition of clenbuterol may be used to substantiate athletes' claims following adverse analytical findings in doping control. However, in meat, the enantiomeric composition was found to be highly variable. Species as well as tissue dependent variances need to be considered in interpreting enantiomer discrimination. Analysis of post administration urines from a controlled experiment comparing the administration of racemic clenbuterol from a registered pharmaceutical preparation and the administration of residue-containing meat and liver (nonracemic mixture) from treated animals is reported. Furthermore doping control samples from Mexican U17 World Championship 2011 of the Fédération Internationale de Football Association (FIFA), with adverse analytical findings for clenbuterol, were re-analysed.
Subject(s)
Clenbuterol/urine , Drug Residues/analysis , Food Contamination/analysis , Meat/analysis , Performance-Enhancing Substances/urine , Adult , Animals , Cattle , Chromatography, Liquid , Clenbuterol/administration & dosage , Clenbuterol/chemistry , Doping in Sports/prevention & control , Drug Residues/chemistry , Healthy Volunteers , Humans , Liver/chemistry , Male , Muscles/chemistry , Performance-Enhancing Substances/administration & dosage , Performance-Enhancing Substances/chemistry , Stereoisomerism , Substance Abuse Detection/methods , Tandem Mass SpectrometryABSTRACT
Creatine is a popular ergogenic supplement in sports nutrition. Yet, supplementation of creatine occasionally caused adverse effects such as gastrointestinal complaints, muscle cramps and an increase in body weight. Creatine monohydrate has already been evaluated by different competent authorities and several have come to the conclusion that a daily intake of 3 g creatine per person is unlikely to pose safety concerns, focusing on healthy adults with exclusion of pregnant and breastfeeding women. Possible vulnerable subgroups were also discussed in relation to the safety of creatine. The present review provides an up-to-date overview of the relevant information with special focus on human studies regarding the safety of creatine monohydrate and other marketed creatine forms, in particular creatine pyruvate, creatine citrate, creatine malate, creatine taurinate, creatine phosphate, creatine orotate, creatine ethyl ester, creatine pyroglutamate, creatine gluconate, and magnesium creatine chelate. Limited data are available with regard to the safety of the latter creatine forms. Considering an acceptable creatine intake of 3 g per day, most of the evaluated creatine forms are unlikely to pose safety concerns, however some safety concerns regarding a supplementary intake of creatine orotate, creatine phosphate, and magnesium creatine chelate are discussed here.
Subject(s)
Creatine/administration & dosage , Dietary Supplements , Performance-Enhancing Substances/administration & dosage , Sports Nutritional Physiological Phenomena , Animals , Consumer Product Safety , Creatine/chemistry , Dose-Response Relationship, Drug , Humans , Mitochondria/drug effects , Mitochondria/metabolism , Models, Animal , Muscle Cells/drug effects , Muscle Cells/metabolism , Muscle, Skeletal/drug effects , Muscle, Skeletal/metabolism , Performance-Enhancing Substances/chemistry , PhosphorylationABSTRACT
The detection of the abuse of pseudo-endogenous steroids (testosterone and/or its precursors) is currently based on the application of the steroid module of the World Anti-Doping Agency (WADA) Athletes' Biological Passport (ABP), implemented through ADAMS. Diagnostic metabolites are monitored for every athlete and statistically evaluated with a predictive Bayesian approach. In the case of suspicious samples, the data of the ABP are confirmed and the isotope ratio mass spectrometry (IRMS) test is activated. We have previously demonstrated that IRMS enables confirmation of the non-endogenous origin of pseudo-endogenous steroids in otherwise non-suspicious samples, after a longitudinal evaluation of the ABP, even after the inclusion of additional long-term diagnostic hydroxylated metabolites, and that the delta values of the parameters obtained during the IRMS confirmation process presented much less variability compared to the parameters of the ABP. The aim of the present work is to evaluate the application of the same methodology used for the evaluation of the ABP, on the delta values of the pseudo-endogenous steroids monitored. The effectiveness of the proposed model has been assessed on samples obtained after controlled administrations of oral androstenedione and transdermal testosterone. The results support the conclusion that, if applied, the longitudinal evaluation of the IRMS data allows the detection of positive samples that otherwise will be reported as atypical findings (ATF), improving the efficacy of the fight against doping in sport. This approach, by narrowing the individual acceptable range, could possibly improve the detection of the intake of preparations of synthetic origin with delta values close to or overlapping those of endogenously produced steroids. Copyright © 2016 John Wiley & Sons, Ltd.
Subject(s)
Anabolic Agents/chemistry , Androstenedione/analysis , Gas Chromatography-Mass Spectrometry/methods , Isotopes/chemistry , Performance-Enhancing Substances/analysis , Testosterone/analysis , Anabolic Agents/metabolism , Androstenedione/chemistry , Androstenedione/metabolism , Athletes , Doping in Sports , Humans , Performance-Enhancing Substances/chemistry , Testosterone/chemistry , Testosterone/metabolismABSTRACT
In 2013 the Dutch authorities issued a warning against a dietary supplement that was linked to 11 reported adverse reactions, including heart problems and in one case even a cardiac arrest. In the UK a 20-year-old woman, said to have overdosed on this supplement, died. Since according to the label the product was a herbal mixture, initial LC-MS/MS analysis focused on the detection of plant toxins. Yohimbe alkaloids, which are not allowed to be present in herbal preparations according to Dutch legislation, were found at relatively high levels (400-900 mg kg(-1)). However, their presence did not explain the adverse health effects reported. Based on these effects the supplement was screened for the presence of a ß-agonist, using three different biosensor assays, i.e. the validated competitive radioligand ß2-adrenergic receptor binding assay, a validated ß-agonists ELISA and a newly developed multiplex microsphere (bead)-based ß-agonist assay with imaging detection (MAGPIX(®)). The high responses obtained in these three biosensors suggested strongly the presence of a ß-agonist. Inspection of the label indicated the presence of N-isopropyloctopamine. A pure standard of this compound was bought and shown to have a strong activity in the three biosensor assays. Analysis by LC-full-scan high-resolution MS confirmed the presence of this 'unknown known' ß3-agonist N-isopropyloctopamine, reported to lead to heart problems at high doses. A confirmatory quantitative analysis revealed that one dose of the preparation resulted in an intake of 40-60 mg, which is within the therapeutic range of this compound. The case shows the strength of combining bioassays with chemical analytical techniques for identification of illegal pharmacologically active substances in food supplements.
Subject(s)
Adrenergic beta-3 Receptor Agonists/poisoning , Antipyrine/analogs & derivatives , Appetite Depressants/adverse effects , Dietary Supplements/adverse effects , Food Contamination , Heart Diseases/etiology , Plant Preparations/adverse effects , Adrenergic beta-3 Receptor Agonists/analysis , Alkaloids/analysis , Alkaloids/toxicity , Anabolic Agents/adverse effects , Anabolic Agents/chemistry , Anabolic Agents/poisoning , Anabolic Agents/standards , Antipyrine/analysis , Antipyrine/poisoning , Appetite Depressants/chemistry , Appetite Depressants/poisoning , Appetite Depressants/standards , Biosensing Techniques , Dietary Supplements/analysis , Dietary Supplements/poisoning , Dietary Supplements/standards , Food Inspection , Food Labeling , Foodborne Diseases/etiology , Foodborne Diseases/mortality , Foodborne Diseases/therapy , Heart Diseases/mortality , Heart Diseases/therapy , Hospitalization , Humans , Internet , Netherlands , Nootropic Agents/adverse effects , Nootropic Agents/chemistry , Nootropic Agents/poisoning , Nootropic Agents/standards , Pausinystalia/adverse effects , Pausinystalia/chemistry , Performance-Enhancing Substances/adverse effects , Performance-Enhancing Substances/chemistry , Performance-Enhancing Substances/poisoning , Performance-Enhancing Substances/standards , Plant Preparations/chemistry , Plant Preparations/poisoning , Plant Preparations/standardsABSTRACT
Stabilizing the labile factor HIF (hypoxia inducible factor) for therapeutic use has led to the development of various molecules by pharmaceutical companies. These HIF stabilizers show promising erythropoiesis stimulating capacities and are of great interest for patients with chronical kidney disease and anemia. Amongst them FG-4592 from FibroGen is now under phase 3 of clinical studies. While this drug is still under investigation, a parallel market already allows to buy this product, which could be tempting for some athletes willing to increase their performances. To avoid such a use for doping purpose, WADA has listed HIF stabilizers and FG-4592 in particular as prohibited substances since 2011 and some anti-doping laboratories have developed a technique of identification of FG-4592 in urine. Here, we described the first case ever identified by an anti-doping laboratory of an athlete using FG-4592. Detection and confirmation in urinary samples was performed by LC-MS/MS. In addition, potential indirect markers erythropoietin (EPO) and hematological parameters followed in the Athlete Biological Passport (ABP) were analyzed during and after the period of use but showed no profound alterations. Only ABPS (abnormal blood profile score) reached (but did not exceed) the upper limit proposed by the ABP adaptive model just after the period of use of FG-4592. Altogether this case sends a warning for anti-doping laboratories which now must strengthen surveillance on HIF stabilizers and develop sensitive methods of detection for this new class of drugs.